Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019
February 21 2019 - 4:15PM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that it will host a live conference
call and webcast at 8:00 a.m. ET on Wednesday, March 6, 2019 to
report its fourth quarter and full year 2018 financial results and
provide a corporate update.
To access the live conference call, please dial 866-922-5184
(domestic) or 409-937-8950 (international), and refer to conference
ID 8294495. A webcast of the call will also be available under
“Events & Presentations” in the Investors section of the
Moderna website at https://investors.modernatx.com/. The archived
webcast will be available on Moderna’s website approximately two
hours after the conference call and will be available for 30 days
following the call.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create
a new class of transformative medicines for patients. mRNA
medicines are designed to direct the body’s cells to produce
intracellular, membrane or secreted proteins that have a
therapeutic or preventive benefit with the potential to address a
broad spectrum of diseases. Moderna’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing the Company the capability to pursue in
parallel a robust pipeline of new development
candidates. Moderna is developing therapeutics and
vaccines for infectious diseases, immuno-oncology, rare diseases
and cardiovascular diseases, independently and with strategic
collaborators.
Headquartered in Cambridge,
Mass., Moderna currently has strategic alliances for
development programs with AstraZeneca, Plc. and Merck,
Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of
Defense, and the Biomedical Advanced Research and
Development Authority (BARDA), a division of the Office
of the Assistant Secretary for Preparedness and
Response (ASPR) within the U.S. Department of Health and
Human Services (HHS). Moderna has been ranked in the
top ten of Science’s list of top biopharma industry
employers for the past four years. To learn more,
visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190221005753/en/
Moderna Contacts:Investors:Lorence KimChief
Financial Officer617-209-5849Lorence.kim@modernatx.com
Media:Jason GlashowHead, Corporate
Communications617-674-5648Jason.glashow@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From May 2023 to May 2024